Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (CURRENTLY AMENDED) A compound of the following Formula 1:



wherein

R_A is a C_2 to C_{30} saturated or unsaturated hydrocarbon chain;

R_{10}, R_{11}, R_{13}, R_{14} and R_3 each independently represent H, OH, a $C_{1\text{-}6}$ ether, or a saturated or unsaturated hydrocarbon chain which may be substituted with one or more of nitro, halogen, amino, hydroxyl, ketone or aldehyde group [[;]] ,and wherein at least one of R_{10}, R_{11} and R_{13} represents OH;

optionally there is a double bond between C_2 and C_3 of the C ring;

n represents 0 or 1; and

R_B is a C_2 to C_{15} saturated or unsaturated hydrocarbon chain, and where R_B is present, R_A and R_B are both C_2 to C_{12} aliphatic alkyl chains.

2. (CANCELLED)

3. (CURRENTLY AMENDED) The compound of claim [[2]] 1, wherein R_{10} and/or R_{11} represents OH.

4. (PREVIOUSLY PRESENTED) The compound of claim 1, wherein R_3, R_{11} and R_{13} all represent OH.

5. (PREVIOUSLY PRESENTED) The compound of claim 1, wherein R_3, R_{10} and R_{13} all represent OH.

6. (PREVIOUSLY PRESENTED) The compound of claim 1, wherein there is a double bond between C_2 and C_3 of the C ring.

7. (PREVIOUSLY PRESENTED) The compound of claim 1, wherein the backbone of R_A has eight, nine or ten carbon atoms.

8. (PREVIOUSLY PRESENTED) The compound of claim 1, wherein R_A is attached to position 7 of the A ring of the flavonoid group.

9. (PREVIOUSLY PRESENTED) The compound of claim 1, wherein R_A has the following structure:



wherein
n is an integer from 1 to 7; and
m is an integer from 1 to 7.

10. (PREVIOUSLY PRESENTED) The compound of claim 1, wherein R_A has the following structure:



11. (PREVIOUSLY PRESENTED) The compound of claim 1, wherein R_A has the following structure:



wherein n is an integer from 2 to 27.

12. (PREVIOUSLY PRESENTED) The compound of claim 1, wherein R_A has the following



structure:

wherein

x is an integer from 1 to 25;

y is an integer from 1 to 25;

and wherein x + y = 25 or less.

13. (PREVIOUSLY PRESENTED) The compound of claim 1, wherein R_A has the following



structure:

wherein

n is an integer from 1 to 7; and

m is an integer from 1 to 7.

14. (CURRENTLY AMENDED) The compound of claim 1, wherein the flavonoid group has one of the following structures:





15. (PREVIOUSLY PRESENTED) The compound of claim 1 having one of the following structures:





























16. (PREVIOUSLY PRESENTED) A composition comprising a compound of claim 1 and at least one pharmaceutical excipient or carrier.

17. (PREVIOUSLY PRESENTED) The composition of claim 16 which is a sunscreen.

18. (ORIGINAL) A method of preventing UV damage to the skin of a mammalian animal, said method comprising administering a therapeutically effective amount of the composition of Claim 17 to said skin prior to UV exposure.

19. (ORIGINAL) The method as claimed in Claim 18 wherein said mammalian animal is a human.

20. (PREVIOUSLY PRESENTED) The method of claim 18, wherein said composition is applied topically to said skin.

21. (PREVIOUSLY PRESENTED) The composition of claim 16 which is a skincare composition.

22. (PREVIOUSLY PRESENTED) The composition of claim 21, wherein said composition further comprises emollients and moisturisers.

23. (CANCELLED)

24. (PREVIOUSLY PRESENTED) A foodstuff stabiliser composition comprising a compound of claim 1.

25. (PREVIOUSLY PRESENTED) The composition of claim 24, wherein said composition is in the form of an emulsion having a low fat:high water content.

26. (PREVIOUSLY PRESENTED) A method of treating a patient having a disease or disorder involving oxidative damage, said method comprising selecting a patient in need thereof,

and administering a therapeutically effective amount of the composition of Claim 16 to said patient.

27. (PREVIOUSLY PRESENTED) The method of claim 26, wherein said patient is a human.

28. (PREVIOUSLY PRESENTED) The method of claim 26, wherein the disease or disorder involving oxidative damage is selected from the group consisting of cancer, heart disease, neurological disorders, auto-immune disorders, ischaemia-reperfusion injury, diabetic complications, septic shock, hepatitis, atherosclerosis and complications arising from HIV or Hepatitis B.

29. (PREVIOUSLY PRESENTED) The method of claim 28, wherein the disease or disorder is an ischaemia-reperfusion injury or Alzheimer's disease.

30. (CURRENTLY AMENDED) A prophylactic method of treatment to prevent or reduce the severity of a disease or disorder involving oxidative damage in the tissues of a patient, said method comprising selecting a patient ~~patent~~ in need thereof, and administering a therapeutically effective amount of the composition of Claim 16 to said patient.

31. (PREVIOUSLY PRESENTED) The method of claim 30, wherein said patient is a human.

32. (PREVIOUSLY PRESENTED) The method of claim 30, wherein the disease or disorder involving oxidative damage is selected from the group consisting of cancer, heart disease, neurological disorders, auto-immune disorders, ischaemia-reperfusion injury, diabetic complications, septic shock, hepatitis, atherosclerosis and complications arising from HIV or Hepatitis B.

33. (PREVIOUSLY PRESENTED) The method of claim 32, wherein the disease or disorder is an ischaemia-reperfusion injury or Alzheimer's disease.

34. (CANCELLED)

35. (CANCELLED)

36. (PREVIOUSLY PRESENTED) A method of manufacturing a compound of Formula 1 as claimed in claim 1, said method comprising providing an intermediate compound A and an intermediate compound B, wherein intermediate compound A has the structure R_AM wherein M is a metal or metalloid group where the metal is directly attached to R_A, and R_A is a C_2 to C_{30} saturated or unsaturated alkyl chain, and R_AM is capable of participating in transition metal catalysed cross-coupling reactions;
and intermediate compound B has the following structure:
wherein



R_{12} represents OH or an O-protecting group
R_3, R_{10}, R_{11}, R_{13}, and R_{14} each independently represent H, OH, C_1 to C_4 aliphatic alkyl group or an O-protecting group where required, and optionally there is a double bond between C_2 and C_3 of the C ring;
X is a halogen, O-trifluoromethane sulphonate or any other group used in cross-coupling reactions; and
m = 1 or 2,

and reacting intermediate compound A with intermediate compound B by transition metal catalysed cross-coupling reactions and subsequently deprotecting at least one OH group.

37. (PREVIOUSLY PRESENTED) The method of claim 36, wherein R_AM is selected from the group consisting of an organomagnesium, organozinc, organoboron and an organotin compound.

38. (PREVIOUSLY PRESENTED) The method of claim 36, wherein the catalyst is a palladium, nickel or iron complex.

39. (PREVIOUSLY PRESENTED) A method of manufacturing a compound of Formula 1 as claimed in claim 1, said method comprising providing an intermediate Compound C and an intermediate Compound D, wherein said intermediate Compound C has the structure R_ACHCHR wherein R_A is as defined in Formula 1, and wherein intermediate Compound D has a structure:



or


40. (PREVIOUSLY PRESENTED) The method of claim 39, wherein the catalyst is:

41. (CURRENTLY AMENDED) A method of manufacturing a compound of Formula 1 as claimed in claim 1, said method comprising providing an intermediate Compound E of formula:



or



and constructing a flavonol core on said intermediate Compound E.

42. (PREVIOUSLY PRESENTED) The method of claim 41, wherein said flavonol core is formed by Algar-Flynn-Oyamada (AFO) oxidation.

43. (PREVIOUSLY PRESENTED) The method of claim 41, wherein said flavanol core is formed by Baker-Verkataraman rearrangement.

44. (PREVIOUSLY PRESENTED) The method of claim 41, wherein said intermediate Compound E is formed by a transition metal catalysed cross-coupling reaction.

45. (PREVIOUSLY PRESENTED) The method of claim 41, wherein said intermediate Compound E is formed by alkene cross-metathesis.

46. (NEW) The compound of claim 1, wherein the backbone of R_A has from 6 to 15 carbon atoms.